Immunocore Holdings plc (IMCR) Next Earnings Date & Expected ±9.2% Move

IMCR scores 24 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 2 of 20, reflecting ROIC of -35% and FCF yield of -0.93%, which indicates the business is not currently generating returns on invested capital or free cash flow relative to its market value. The Whale 13F Flow pillar scores 8 of 20, pointing to institutional accumulation and options positioning that is present but not decisive. The Insider Conviction pillar scores 3 of 20, based on SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 3 of 20, with a Beta of 1.0 and a sector sensitivity noted in the rating. The Forensic Balance Sheet pillar scores 8 of 20, citing an Altman Z-Score of 1.4, a Piotroski F-Score of 5 of 9, and Debt/Equity of 0.5. For a prospective investor, the upside case rests on any future improvement in cash generation and a balance sheet that the rating describes as adequate on Debt/Equity; the valuation tradeoff is that the stock is priced at $31.27 without reported earnings-based multiples, so the investor is effectively underwriting a turnaround rather than paying for demonstrated profit. The principal risks flagged by the rating are negative ROIC, negative free cash flow yield, and a distress-zone Altman Z-Score.

Immunocore Holdings plc is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..6B. FY 2025 revenue was $400.0M against a 96% gross margin per the market data.

Revenue grew from $249.4M in FY 2023 to $400.0M in FY 2025 while operating losses narrowed from -$59.6M to -$45.4M over the same span. Per the market data, operating margin is -11.3% and net margin is -8.9%, and ROIC is -35%. The Altman Z-Score is 1.4 and the Piotroski F-Score is 5 of 9, with Debt/Equity of 0.5. Cash was $467.7M at FY 2025 and FCF was -$15.1M in that year.

• 🐂 Primary Bull Case: Revenue grew from $249.4M in FY 2023 to $400.0M in FY 2025 while operating losses narrowed, and cash stood at $467.7M. With Fundamental Cash Engine at 2/20 (ROIC -35.0%, FCF yield -0.93%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $27.50 – $40.72 52-week range.
• 🐻 Primary Bear Case: ROIC of -35%, FCF yield of -0.93%, and an Altman Z-Score of 1.4 leave the Roarable rating at 24 with a Strong Sell verdict. Investors must weigh current valuation against -11.3% operating margins and a 1.00 macro beta if sector demand softens.

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for IMCR. The second-order ripples a prospective investor would want to track, such as dependency on a single trial program or partner, are not resolved by the available data.

• Key Question #1: What specific products or trial programs drive the reported FY 2025 revenue of $400.0M, and how concentrated is that revenue?
• Key Question #2: Why does the FY 2025 FCF of -$15.1M contrast with the FY 2024 FCF of $20.9M, and what drove the swing?
• Key Question #3: What did the Q2 2026 earnings call and the Type 1 Diabetes trial updates actually report in financial or clinical terms?